about
What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?Depressive symptoms in neurodegenerative diseasesMedication nonadherence in Parkinson's diseaseReward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson’s diseaseTreatment of psychosis and dementia in Parkinson's disease.Treatment of advanced Parkinson's diseaseSocial behavioral changes in MPTP-treated monkey model of Parkinson's disease.Emotional blunting following left basal ganglia stroke: the role of depression and fronto-limbic functional alterations.Heterogeneous patterns of tissue injury in NARP syndromeA randomized trial of individual versus group-format exercise and self-management in individuals with Parkinson's disease and comorbid depression.Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson's disease.Depression and Parkinson's disease: current knowledge.The dopaminergic system in the aging brain of Drosophila.Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serumIndependent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA.Parkinson's disease permanent care unit: managing the chronic-palliative interface.Apathy in Parkinson's disease is related to executive function, gender and age but not to depression.Neurobiology of depression and anxiety in Parkinson's diseaseThe Natural History of Depression in Parkinson's Disease within 30-Month Follow-Up.Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyondAn update expert opinion on management and research strategies in Parkinson's disease psychosisCerebral correlates of psychotic syndromes in neurodegenerative diseasesOlfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease.Stress, depression and Parkinson's disease.Association between antidepressants and falls in Parkinson's disease.Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice.Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementiaEvaluation and management of the non-motor features of Parkinson's disease.The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's DiseaseThe pons and human affective processing--Implications for Parkinson's disease.Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United StatesAdjustment disorder and risk of Parkinson's diseaseMolecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.A pilot study on the benefit of cognitive rehabilitation in Parkinson's disease.Clinical characteristics of fatigued Parkinson's patients and the response to dopaminergic treatment.Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx)Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.Neuropsychiatric symptoms in untreated Parkinson's disease.
P2860
Q26767268-BCC360F0-099F-4B7F-A0D7-7B32D3D63320Q26798063-149352A5-028A-45FE-A7ED-DA3D47AA5CC4Q26823300-ADD680F1-B43B-4B74-9953-9FBECD2B884AQ27303483-B73E9E79-4DB7-4218-B1CA-DF62F064B713Q30358337-48E48570-B20E-42B2-BD8B-52A6B9E6A7A6Q30476968-12CBEBA1-935C-47C4-89EB-205CAE4732E2Q30621723-069B72A7-AD05-49CB-A72C-905591052F65Q33605714-723E2B5A-9D30-4BBA-BA79-A918BBD29E13Q33720822-6A0FBDF7-973A-4976-A520-09D5F4E05642Q33739875-E5C47DD6-3380-4B9A-B5CA-2205FF434EA7Q33840503-2F9F7CDC-B2D9-4DBA-845D-46BB096398FEQ33855598-F0EA200F-8009-4CC1-8C5C-27789637D684Q34382560-BF11FBB9-873D-410D-AED3-07FC07F9DF7FQ34408857-24E6AE9D-E4B6-4B1B-8B08-FC5E4F6766BDQ34452085-032BD42F-DF42-48DA-9410-21D0C0A763CFQ34481209-856EA2ED-0508-4CB0-A92D-60FE7A7E4CC3Q34883298-97A3997B-7128-4EA8-BEF1-193F72C0D17BQ34969055-0B4A8731-F61E-4449-B479-C38B7C0080E2Q35028706-D8826273-0FA8-4FFE-8650-6A5951A3A399Q35098556-A33EBD44-8921-4981-A0BE-D650463EB87DQ35120721-348D538C-C21C-43B9-8DE1-01BBFAD0DE30Q35154278-C0D91DCF-B6B0-4A94-9A0E-8311E4DC11D9Q35194993-01CF0FD8-1AA5-40D7-A215-BEC176FE6216Q35201409-C575F2C7-E5DE-4ED7-8EF6-8D7755EB87F2Q35713356-95F5464E-9440-46E3-AA4D-D82B5866DE34Q35826600-1AA08133-F278-4554-AF7F-211C9C69EBC1Q35893872-5D594563-CBA0-4CB1-94CB-9DC4E82191E8Q36004081-8FA0417A-266E-464A-A031-EABE2D789E58Q36443721-171D73C4-5F0D-4C43-ABA8-F4EDAB1FFF43Q36494212-DA9272CA-516A-43E0-8686-999CA90F652EQ36541032-C0597D7B-F060-4080-840D-4B595751B638Q36582373-56F62363-538C-4355-B75F-DCD00F02FA13Q36717160-162DFEFC-C37B-494D-BBCD-04D8602DECFDQ36724965-D0A94AEE-302B-4458-98C6-04D2E4CDE67CQ36737558-979AAD9C-09E0-4058-A1BD-910D45248F57Q36890515-ECA9AB9A-F0E1-4833-B346-A5961103633FQ36944738-18359EDD-2BA8-414F-BA3D-4DDC21910A34Q36946063-C70BEE12-6DA3-4031-9182-F85B21F39772Q37395632-ACA0FB9C-39BD-4CAA-A63E-55C2E1600F27Q37714081-918F94CD-F1C5-438B-8637-C977F3ECA9B4
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Neuropsychiatric symptoms in Parkinson's disease.
@en
Neuropsychiatric symptoms in Parkinson's disease.
@nl
type
label
Neuropsychiatric symptoms in Parkinson's disease.
@en
Neuropsychiatric symptoms in Parkinson's disease.
@nl
prefLabel
Neuropsychiatric symptoms in Parkinson's disease.
@en
Neuropsychiatric symptoms in Parkinson's disease.
@nl
P2860
P356
P1433
P1476
Neuropsychiatric symptoms in Parkinson's disease.
@en
P2093
Laura Marsh
P2860
P304
P356
10.1002/MDS.22589
P407
P577
2009-11-01T00:00:00Z